Zum Inhalt springen

Medscape: Experimental Drug Targets COVID-19 From Two Angles

  • 1 min read

17.01.2022 – by Reuters Staff | Read the full article here.

(Reuters) – An experimental drug originally being developed to treat influenza is showing promise against SARS-CoV-2 and might defend against COVID-19 from two different directions, researchers said.
The drug, called zapnometinib or ATR-002, could potentially curb the proliferation of the virus in cells and also reduce the exaggerated immune response that contributes to critical illness in severe cases of COVID-19, test tube experiments indicated.